MDPI and ACS Style
Balleza Alejandri, L.R.; Grover Páez, F.; González Campos, E.; Ramos Becerra, C.G.; Cardona Muñóz, E.G.; Pascoe González, S.; Ramos Zavala, M.G.; Reynoso Roa, A.S.; Suárez Rico, D.O.; Beltrán RamÃrez, A.;
et al. Correction: Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial. J. Cardiovasc. Dev. Dis. 2024, 11, 182. J. Cardiovasc. Dev. Dis. 2024, 11, 314.
https://doi.org/10.3390/jcdd11100314
AMA Style
Balleza Alejandri LR, Grover Páez F, González Campos E, Ramos Becerra CG, Cardona Muñóz EG, Pascoe González S, Ramos Zavala MG, Reynoso Roa AS, Suárez Rico DO, Beltrán RamÃrez A,
et al. Correction: Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial. J. Cardiovasc. Dev. Dis. 2024, 11, 182. Journal of Cardiovascular Development and Disease. 2024; 11(10):314.
https://doi.org/10.3390/jcdd11100314
Chicago/Turabian Style
Balleza Alejandri, Luis Ricardo, Fernando Grover Páez, Erick González Campos, Carlos G. Ramos Becerra, Ernesto Germán Cardona Muñóz, Sara Pascoe González, MarÃa Guadalupe Ramos Zavala, Africa Samantha Reynoso Roa, Daniel Osmar Suárez Rico, Alberto Beltrán RamÃrez,
and et al. 2024. "Correction: Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial. J. Cardiovasc. Dev. Dis. 2024, 11, 182" Journal of Cardiovascular Development and Disease 11, no. 10: 314.
https://doi.org/10.3390/jcdd11100314
